Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ImmunityBio (IBRX) Amortization - Intangibles (2016 - 2021)

ImmunityBio has reported Amortization - Intangibles over the past 7 years, most recently at -$23000.0 for Q2 2021.

  • Quarterly Amortization - Intangibles rose 52.08% to -$23000.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was -$836000.0 through Jun 2021, down 808.7% year-over-year, with the annual reading at -$858000.0 for FY2020, 28700.0% down from the prior year.
  • Amortization - Intangibles was -$23000.0 for Q2 2021 at ImmunityBio, up from -$384000.0 in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $42000.0 in Q2 2019 and troughed at -$572000.0 in Q1 2017.
  • The 5-year median for Amortization - Intangibles is -$81000.0 (2018), against an average of -$172823.5.
  • Year-over-year, Amortization - Intangibles surged 133.33% in 2019 and then plummeted 3100.0% in 2020.
  • A 5-year view of Amortization - Intangibles shows it stood at -$299000.0 in 2017, then surged by 72.91% to -$81000.0 in 2018, then surged by 85.19% to -$12000.0 in 2019, then plummeted by 3100.0% to -$384000.0 in 2020, then surged by 94.01% to -$23000.0 in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Amortization - Intangibles are -$23000.0 (Q2 2021), -$384000.0 (Q4 2020), and -$381000.0 (Q3 2020).